Advertisement

Average treatment effect of facility hepatopancreatobiliary cancer volume on survival of non-resected pancreatic adenocarcinoma

      Abstract

      Background

      To examine the average treatment effect of hepato-pancreato-biliary (HPB) cancer volume on survival outcomes of patients with non-resected pancreatic adenocarcinoma (PDAC).

      Methods

      We queried the National Cancer Database (2004–2018) for patients with HPB malignancies (PDAC, pancreatic neuroendocrine neoplasms, hepatocellular carcinoma, biliary tract cancers). We determined the 25th, 50th, and 75th percentiles based on the total annual HPB volume. We then identified patients with non-resected PDAC. We utilized inverse probability (IP)-weighted Cox regression to estimate the effect of facility volume on overall survival (OS).

      Results

      We identified 710,988 patients with HPB malignancies. The 25th, 50th, and 75th percentiles of total annual HPB volume were 32, 71, and 177 cases/year, respectively. We included a total of 196,150 patients with non-resected PDAC.
      Patients treated at ≥25th, ≥50th, and ≥75th percentile facilities had improved median OS compared to those treated at facilities below these thresholds (5.8 vs. 4.2months, 6.5 vs. 4.5months, 7.5 vs. 4.8months, respectively; p < 0.001 for all). Treatment at facilities ≥25th, ≥50th, and ≥75th percentile resulted in lower hazards of death than treatment at lower-percentile facilities (HR: 0.87, 95% CI: 0.84–0.90; HR: 0.87, 95% CI: 0.83–0.91; HR: 0.85, 95% CI: 0.79–0.91, respectively).

      Conclusion

      Our data suggest that consolidation of care of patients with PDAC to high-volume centers may be beneficial even in the nonoperative setting.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to HPB
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Siegel R.L.
        • Miller K.D.
        • Fuchs H.E.
        • Jemal A.
        Cancer statistics, 2022.
        CA Cancer J Clin. 2022; 72: 7-33https://doi.org/10.3322/caac.21708
        • Rawla P.
        • Sunkara T.
        • Gaduputi V.
        Epidemiology of pancreatic cancer: global trends, etiology and risk factors.
        World J Oncol. Feb 2019; 10: 10-27https://doi.org/10.14740/wjon1166
        • Bilimoria K.Y.
        • Bentrem D.J.
        • Ko C.Y.
        • Stewart A.K.
        • Winchester D.P.
        • Talamonti M.S.
        National failure to operate on early stage pancreatic cancer.
        Ann Surg. Aug 2007; 246: 173-180https://doi.org/10.1097/SLA.0b013e3180691579
        • Watson M.D.
        • Miller-Ocuin J.L.
        • Driedger M.R.
        • Beckman M.J.
        • McKillop I.H.
        • Baker E.H.
        • et al.
        Factors associated with treatment and survival of early stage pancreatic cancer in the era of modern chemotherapy: an analysis of the national cancer database.
        J Pancreat Cancer. 2020; 6: 85-95https://doi.org/10.1089/pancan.2020.0011
        • Byrd K.
        • Alqahtani S.
        • Yopp A.C.
        • Singal A.G.
        Role of multidisciplinary care in the management of hepatocellular carcinoma.
        Semin Liver Dis. Jan 2021; 41: 1-8https://doi.org/10.1055/s-0040-1719178
        • Grossberg A.J.
        • Chu L.C.
        • Deig C.R.
        • Fishman E.K.
        • Hwang W.L.
        • Maitra A.
        • et al.
        Multidisciplinary standards of care and recent progress in pancreatic ductal adenocarcinoma.
        CA Cancer J Clin. Sep 2020; 70: 375-403https://doi.org/10.3322/caac.21626
        • Salgia R.
        • Mendiratta V.
        The multidisciplinary management of hepatocellular carcinoma.
        Clin Liver Dis. Jun 2021; 17: 405-408https://doi.org/10.1002/cld.1068
        • Valle J.W.
        • Kelley R.K.
        • Nervi B.
        • Oh D.Y.
        • Zhu A.X.
        Biliary tract cancer.
        Lancet. Jan 30 2021; 397: 428-444https://doi.org/10.1016/S0140-6736(21)00153-7
        • Guo X.Z.
        • Cui Z.M.
        • Liu X.
        Current developments, problems and solutions in the non-surgical treatment of pancreatic cancer.
        World J Gastrointest Oncol. Feb 2013; 5: 20-28https://doi.org/10.4251/wjgo.v5.i2.20
        • Ahola R.
        • Sand J.
        • Laukkarinen J.
        Pancreatic resections are not only safest but also most cost-effective when performed in a high-volume centre: a Finnish register study.
        Pancreatology. Jul 2019; 19: 769-774https://doi.org/10.1016/j.pan.2019.06.007
        • Jogerst K.M.
        • Chang Y.H.
        • Etzioni D.A.
        • Mathur A.K.
        • Habermann E.B.
        • Wasif N.
        Identifying the Optimal case-volume threshold for pancreatectomy in contemporary practice.
        Am J Surg. Mar 2021; https://doi.org/10.1016/j.amjsurg.2021.03.030
        • Kutlu O.C.
        • Lee J.E.
        • Katz M.H.
        • Tzeng C.D.
        • Wolff R.A.
        • Varadhachary G.R.
        • et al.
        Open pancreaticoduodenectomy case volume predicts outcome of laparoscopic approach: a population-based analysis.
        Ann Surg. Mar 2018; 267: 552-560https://doi.org/10.1097/SLA.0000000000002111
        • Swanson R.S.
        • Pezzi C.M.
        • Mallin K.
        • Loomis A.M.
        • Winchester D.P.
        The 90-day mortality after pancreatectomy for cancer is double the 30-day mortality: more than 20,000 resections from the national cancer data base.
        Ann Surg Oncol. Dec 2014; 21: 4059-4067https://doi.org/10.1245/s10434-014-4036-4
        • Torphy R.J.
        • Friedman C.
        • Halpern A.L.
        • Ahrendt S.A.
        • McCarter M.D.
        • Del Chiaro M.
        • et al.
        Implementation of minimally invasive pancreaticoduodenectomy at low and high-volume centers.
        J Surg Res. Dec 2021; 268: 720-728https://doi.org/10.1016/j.jss.2021.06.086
        • Wegner R.E.
        • Verma V.
        • Hasan S.
        • Schiffman S.
        • Thakkar S.
        • Horne Z.D.
        • et al.
        Incidence and risk factors for post-operative mortality, hospitalization, and readmission rates following pancreatic cancer resection.
        J Gastrointest Oncol. Dec 2019; 10: 1080-1093https://doi.org/10.21037/jgo.2019.09.01
        • Ratnayake B.
        • Pendharkar S.A.
        • Connor S.
        • Koea J.
        • Sarfati D.
        • Dennett E.
        • et al.
        Patient volume and clinical outcome after pancreatic cancer resection: a contemporary systematic review and meta-analysis.
        Surgery. Jan 2022; https://doi.org/10.1016/j.surg.2021.11.029
        • Hue J.J.
        • Sugumar K.
        • Markt S.C.
        • Hardacre J.M.
        • Ammori J.B.
        • Rothermel L.D.
        • et al.
        Facility volume-survival relationship in patients with early-stage pancreatic adenocarcinoma treated with neoadjuvant chemotherapy followed by pancreatoduodenectomy.
        Surgery. Jul 2021; 170: 207-214https://doi.org/10.1016/j.surg.2020.12.003
        • Adam M.A.
        • Thomas S.
        • Youngwirth L.
        • Pappas T.
        • Roman S.A.
        • Sosa J.A.
        Defining a hospital volume threshold for minimally invasive pancreaticoduodenectomy in the United States.
        JAMA Surg. Apr 2017; 152: 336-342https://doi.org/10.1001/jamasurg.2016.4753
        • Goyal G.
        • Kommalapati A.
        • Bartley A.C.
        • Gunderson T.M.
        • Adjei A.A.
        • Go R.S.
        Association between hospital volume and mortality of patients with metastatic non-small cell lung cancer.
        Lung Cancer. Aug 2018; 122: 214-219https://doi.org/10.1016/j.lungcan.2018.06.025
        • Joshi S.S.
        • Handorf E.A.
        • Zibelman M.
        • Plimack E.R.
        • Uzzo R.G.
        • Kutikov A.
        • et al.
        Treatment facility volume and survival in patients with metastatic renal cell carcinoma: a registry-based analysis.
        Eur Urol. Sep 2018; 74: 387-393https://doi.org/10.1016/j.eururo.2018.05.025
        • Tella S.H.
        • Kommalapati A.
        • Ganti A.K.
        • Marr A.S.
        Association between hospital volume, therapy types, and overall survival in stage III and IV cutaneous malignant melanoma.
        J Natl Compr Cancer Netw. Nov 2019; 17: 1334-1342https://doi.org/10.6004/jnccn.2019.7320
      1. American College of Surgeons. The national cancer database 2018 PUF data dictionary. https://bit.ly/33Y8HWE. Accessed 26.05.22.

      2. The United States Census Bureau. Census regions and divisions of the United States. https://bit.ly/35yPyuX. Accessed 26.05.22.

        • Austin P.C.
        • Stuart E.A.
        Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies.
        Stat Med. Dec 2015; 34: 3661-3679https://doi.org/10.1002/sim.6607
        • Kaufman J.S.
        Marginalia: comparing adjusted effect measures.
        Epidemiology. Jul 2010; 21: 490-493https://doi.org/10.1097/EDE.0b013e3181e00730
        • Greenland S.
        • Pearl J.
        • Robins J.M.
        Causal diagrams for epidemiologic research.
        Epidemiology. Jan 1999; 10: 37-48
        • Tennant P.W.G.
        • Murray E.J.
        • Arnold K.F.
        • Berrie L.
        • Fox M.P.
        • Gadd S.C.
        • et al.
        Use of directed acyclic graphs (DAGs) to identify confounders in applied health research: review and recommendations.
        Int J Epidemiol. May 2021; 50: 620-632https://doi.org/10.1093/ije/dyaa213
        • Elshami M.
        • Hue J.J.
        • Hoehn R.S.
        • Rothermel L.D.
        • Bajor D.
        • Mohamed A.
        • et al.
        A nationwide analysis of clinical trial participation for common hepato-pancreato-biliary malignancies demonstrates survival advantages for subsets of trial patients but disparities in and infrequency of enrollment.
        HPB. Aug 2022; 24: 1280-1290https://doi.org/10.1016/j.hpb.2021.12.022
        • Hue J.J.
        • Katayama E.S.
        • Markt S.C.
        • Elshami M.
        • Saltzman J.
        • Bajor D.
        • et al.
        A nationwide analysis of pancreatic cancer trial enrollment reveals disparities and participation problems.
        Surgery. Nov 2021; https://doi.org/10.1016/j.surg.2021.10.023
        • Beal E.W.
        • Mehta R.
        • Tsilimigras D.I.
        • Hyer J.M.
        • Paredes A.Z.
        • Merath K.
        • et al.
        Travel to a high volume hospital to undergo resection of gallbladder cancer: does it impact quality of care and long-term outcomes?.
        HPB. Jan 2020; 22: 41-49https://doi.org/10.1016/j.hpb.2019.05.004
        • Chapman B.C.
        • Paniccia A.
        • Hosokawa P.W.
        • Henderson W.G.
        • Overbey D.M.
        • Messersmith W.
        • et al.
        Impact of facility type and surgical volume on 10-year survival in patients undergoing hepatic resection for hepatocellular carcinoma.
        J Am Coll Surg. Mar 2017; 224: 362-372https://doi.org/10.1016/j.jamcollsurg.2016.11.011
      3. National Cancer Institute; Surveillance epidemiology and end results program. SEER cancer statistics review, 1975-2018, National Cancer Institute. https://seer.cancer.gov/csr/1975_2018. Accessed 26.05.22.

        • de la Fouchardiere C.
        • Adham M.
        • Marion-Audibert A.M.
        • Duclos A.
        • Darcha C.
        • Berthelet O.
        • et al.
        Management of patients with pancreatic ductal adenocarcinoma in the real-life setting: lessons from the French national hospital database.
        Cancers. Jul 2021; 13https://doi.org/10.3390/cancers13143515
        • Humphrys E.
        • Burt J.
        • Rubin G.
        • Emery J.D.
        • Walter F.M.
        The influence of health literacy on the timely diagnosis of symptomatic cancer: a systematic review.
        Eur J Cancer Care. Jan 2019; 28e12920https://doi.org/10.1111/ecc.12920
        • Noel M.
        • Fiscella K.
        Disparities in pancreatic cancer treatment and outcomes.
        Health Equity. 2019; 3: 532-540https://doi.org/10.1089/heq.2019.0057
        • Oberstein P.E.
        • Olive K.P.
        Pancreatic cancer: why is it so hard to treat?.
        Ther Adv Gastroenterol. Jul 2013; 6: 321-337https://doi.org/10.1177/1756283X13478680
        • Principe D.R.
        • Underwood P.W.
        • Korc M.
        • Trevino J.G.
        • Munshi H.G.
        • Rana A.
        The current treatment paradigm for pancreatic ductal adenocarcinoma and barriers to therapeutic efficacy.
        Front Oncol. 2021; 11688377https://doi.org/10.3389/fonc.2021.688377
        • Katayama E.S.
        • Hue J.J.
        • Bajor D.L.
        • Ocuin L.M.
        • Ammori J.B.
        • Hardacre J.M.
        • et al.
        A comprehensive analysis of clinical trials in pancreatic cancer: what is coming down the pike?.
        Oncotarget. Sep 22 2020; 11: 3489-3501https://doi.org/10.18632/oncotarget.27727
        • Gao X.
        • Schroeder M.C.
        • Lizarraga I.M.
        • Tolle C.L.
        • Mullett T.W.
        • Charlton M.E.
        Improving cancer care locally: study of a hospital affiliate network model.
        J Rural Health. Dec 2021; https://doi.org/10.1111/jrh.12639
        • Farges O.
        • Bendersky N.
        • Truant S.
        • Delpero J.R.
        • Pruvot F.R.
        • Sauvanet A.
        The theory and practice of pancreatic surgery in France.
        Ann Surg. Nov 2017; 266: 797-804https://doi.org/10.1097/SLA.0000000000002399
        • Conroy T.
        • Desseigne F.
        • Ychou M.
        • Bouche O.
        • Guimbaud R.
        • Becouarn Y.
        • et al.
        FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
        N Engl J Med. May 2011; 364: 1817-1825https://doi.org/10.1056/NEJMoa1011923
        • Moore M.J.
        • Goldstein D.
        • Hamm J.
        • Figer A.
        • Hecht J.R.
        • Gallinger S.
        • et al.
        Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group.
        J Clin Oncol. May 2007; 25: 1960-1966https://doi.org/10.1200/JCO.2006.07.9525
        • Von Hoff D.D.
        • Ervin T.
        • Arena F.P.
        • Chiorean E.G.
        • Infante J.
        • Moore M.
        • et al.
        Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine.
        N Engl J Med. Oct 2013; 369: 1691-1703https://doi.org/10.1056/NEJMoa1304369
        • Wang-Gillam A.
        • Li C.P.
        • Bodoky G.
        • Dean A.
        • Shan Y.S.
        • Jameson G.
        • et al.
        Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
        Lancet. Feb 2016; 387: 545-557https://doi.org/10.1016/S0140-6736(15)00986-1
        • Abrams T.A.
        • Meyer G.
        • Meyerhardt J.A.
        • Wolpin B.M.
        • Schrag D.
        • Fuchs C.S.
        Patterns of chemotherapy use in a U.S.-Based cohort of patients with metastatic pancreatic cancer.
        Oncologist. Aug 2017; 22: 925-933https://doi.org/10.1634/theoncologist.2016-0447
        • Hallet J.
        • Davis L.
        • Mahar A.
        • Mavros M.
        • Beyfuss K.
        • Liu Y.
        • et al.
        Benefits of high-volume medical oncology care for noncurable pancreatic adenocarcinoma: a population-based analysis.
        J Natl Compr Cancer Netw. Mar 2020; 18: 297-303https://doi.org/10.6004/jnccn.2019.7361
        • Hallet J.
        • Davis L.E.
        • Mahar A.L.
        • Liu Y.
        • Zuk V.
        • Gupta V.
        • et al.
        Variation in receipt of therapy and survival with provider volume for medical oncology in non-curative esophago-gastric cancer: a population-based analysis.
        Gastric Cancer. Mar 2020; 23: 300-309https://doi.org/10.1007/s10120-019-01012-z
      4. KFF. Health and health coverage in the south: a data update. https://bit.ly/3DBEbxN. Accessed 26.05.22.

        • Boeck S.
        • Hinke A.
        • Wilkowski R.
        • Heinemann V.
        Importance of performance status for treatment outcome in advanced pancreatic cancer.
        World J Gastroenterol. Jan 14 2007; 13: 224-227https://doi.org/10.3748/wjg.v13.i2.224
        • Tas F.
        • Sen F.
        • Odabas H.
        • Kilic L.
        • Keskin S.
        • Yildiz I.
        Performance status of patients is the major prognostic factor at all stages of pancreatic cancer.
        Int J Clin Oncol. Oct 2013; 18: 839-846https://doi.org/10.1007/s10147-012-0474-9